A T-lymphocyte-specific enhancer located 13 kb upstream of the murine CD4 gene was recently shown to be required for the developmentally regulated expression of CD4. We have previously identified three nuclear protein binding sites in this enhancer, one of these sites, CD4-3, is essential for expression and contains two E-box core motifs (CANNTG) adjacent to each other in the sequence TAACAGGTGT-TAGCIGT. In electrophoretic mobility shift assays using the CD4-3 oligonucleotide as a probe, three nuclear protein complexes, termed CD4-3A, -B, and -C, were detected with nuclear extracts from T-cell lines. CD4-3A, which involves nuclear protein binding to the 5' E-box, was detected only with nuclear extracts from lymphoid cells. Specific antisera were used to show that the CD4-3A complex contains a heterodimer or heterooligomer of basic helix-loop-helix transcriptional factors, E12 or a related factor and HEB, which is expressed predominantly in thymus. Consistent with this finding, in vitro-translated E12 and HEB proteins, as homodimers or heterodimers, bound preferentially to the 5' E-box. Point mutations in the 5' E-box, but not in the 3' E-box, abolished CD4 enhancer activity. Furthermore, overexpression of Id, a protein that forms inactive heterodimers with E12/E47, blocked CD4 enhancer activity in T cells. These results suggest that a heterodimer composed of HEB and E12 or a closely related protein plays a critical role in CD4 enhancer function by interacting with the 5' E-box motif of the CD4-3 site in vivo.
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Development of T lymphocytes within the thymus requires appropriately timed expression of several T-cellspecific surface glycoproteins involved in cell-cell interactions. Two of these, CD4 and CD8, are coexpressed on the majority of immature thymocytes and have critical roles in the ensuing progression to functional T cells that express one glycoprotein to the exclusion of the other. The CD4 glycoprotein is specifically expressed on the surface of helper T cells, while CD8 is expressed on cytotoxic T cells. CD4 and CD8 bind to nonpolymorphic regions of major histocompatibility complex class II and class I molecules, respectively (7, 11, 15, 25, 31, 34, 43, 46) . In addition, a cytoplasmic protein tyrosine kinase, p56k , is noncovalently associated with the cytoplasmic domains of both CD4 and CD8 (45, 49, 54, 55) . Upon interaction of the T-cell antigen receptor (TCR) with major histocompatibility complex-bound peptides, CD4 or CD8 and the associated kinase migrate into the vicinity of the TCR complex, increasing its avidity for the major histocompatibility complex molecule (40, 41, 61) . The signals transduced through the collaboration of CD4 and CD8 with the TCR are critical for selection of the T-cell repertoire during thymic ontogeny and for the activation of mature T cells (1, 17, 20, 24, 27, 44) .
Recent evidence suggests that commitment of a thymocyte to express either CD4 or CD8 occurs stochastically and is coordinated with commitment to become a helper or cytotoxic cell, respectively (13) . Elucidation of the mechanism involved in the regulation of CD4 and CD8 gene expression is likely to yield important insight into processes involved in the functional differentiation of T-cell subsets. In earlier work, we have identified and characterized a T-cell-A series of closely related bHLH proteins, E12/E47/ITF1 (22, 36) , ITF2 (22) , and HTF4/HEB (23, 62) , have been cloned from human cDNA expression libraries by screening for binding of labeled E-box sequences. Although these factors are expressed ubiquitously, they are believed to participate in the formation of heterodimeric transcription factors that direct tissue-specific regulation of expression of the immunoglobulin p, and K chain genes, muscle-specific genes, and the insulin gene (2, 12, 33, 37, 50) . In muscle cells, E12-like proteins dimerize with the muscle-cell-specific MyoD family proteins (Myf-5, myogenin, MyoD, and MRF/herculin/Myf-6) and thus mediate expression of muscle-specific genes (14, 33, 59) . The function of such heterodimers is inhibited by expression of the Id proteins, HLH proteins that lack the basic region and dimerize with E12/ E47 to form inactive complexes devoid of DNA binding activity (3, 4, 10, 16, 51) . It has been proposed that through this process Id proteins regulate tissue-specific gene expression during development (26, 32, 51, 60) .
In this study, we have begun to analyze the nuclear factors that bind to the critical CD4-3 site. We have found that an oligomer containing the bHLH proteins HEB and E12, or a protein immunologically related to E12, binds to the 5' E-box of the CD4-3 site and is present in a lymphoid cell-specific nuclear protein complex. Enhancer function was disrupted by mutations that blocked formation of this complex and by expression of Id. These studies suggest that the interaction of HEB and an E12-like protein with the CD4-3 site plays a crucial role in CD4 enhancer function.
MATERIALS AND METHODS
Cell culture. All cell lines were grown in RPMI 1640 medium containing 10% fetal calf serum, 50 puM 2-mercaptoethanol, and antibiotics.
Construction of CAT expression vectors. The pCD4CAT vector, in which the chloramphenicol acetyltransferase (CAT) gene is driven by the CD4 promoter, was prepared by replacing the thymidine kinase promoter fragment of pBLCAT2 (35) with the XbaI-to-XhoI fragment (487 bp) of the CD4 promoter region, which contains the transcription initiation site and 70 bp of the untranslated first exon (33a). The 339-bp minimal CD4 enhancer fragments (BstXI to AvaII) with or without mutations were inserted in the polylinker site at the 5' end of pCD4CAT in a sense orientation.
Transfections and CAT assays. Transfections were performed with the DEAE-dextran procedure (21) with minor modifications (47) . Rous sarcoma virus-luciferase plasmid (2 p,g) was cotransfected to control for transfection efficiency. After 48 h, cells were harvested and lysed by four cycles of freezing and thawing. The lysates were centrifuged at 4°C, and the supernatants were recovered. For the CAT assays, the extracts were further incubated at 56°C for 10 min and centrifuged to remove debris. Protein concentration was determined, and extract containing 100 p,g of protein was assayed for its ability to convert [14C]chloramphenicol to the acetylated form overnight. Quantitation of acetylation ratios was performed with a PhosphorImager system (Molecular Dynamics). Luciferase assays were performed according to the method of Ow et al. (42) poly(dI-dC) and 5 pg of a crude nuclear extract for 15 min in a 30°C water bath. The nuclear extracts were prepared as described by Schreiber et al. (48) . Following binding, the mixture was electrophoresed through a native high-ionicstrength gel (4% acrylamide, 0.05% bisacrylamide, 2.5% glycerol, 50 mM Tris base, 380 mM glycine, 2 mM EDTA).
Electrophoresis was carried out at 30 mA for 2 to 3 h at 4°C.
The gel was dried and autoradiographed with an intensifying screen at -70°C. For competition experiments, specific and nonspecific competitor DNAs (5 to 50 ng) were incubated in the mixture prior to addition of the nuclear extracts. The sequences of wild-type and mutant oligonucleotides for CD4-1 and CD4-3 sites are shown in Fig. 2A . The wild-type oligonucleotides for the KE2 and CD4-2 binding sites are 5'-CAAGGCAGGTGGCCCAC-3' and 5'-AAAAAAGAAC AAAGGGCCTAGAT1T-3', respectively. For the supershift assay, 1 ,ul of antiserum against E12 (16 mg/ml) or of preimmune serum (19 mg/ml), undiluted or diluted 1:5 or 1:25, was added to the mixture. These sera were kindly provided by C. Murre (38) .
Expression screening. Purified fusion protein containing the HLH motif of Syrian hamster shPAN-2 (amino acids 509 to 649; R-554 --A, R-556 -* A [18] ), a heart muscle kinase recognition site, and the FLAG epitope was kindly provided by M. A. Blanar and was labeled with [y-32P]ATP and used to screen 1.8 x 106 plaques of a Xgtll human thymus cDNA library (Clontech, Palo Alto, Calif.) as described previously (5) . The cDNA inserts of clones identified in the screen were inserted into the EcoRI cloning site of pBluescript, and double-stranded sequencing was performed with Sequenase (United States Biochemical, Cleveland, Ohio).
In vitro transcription and translation. pHEB was constructed by inserting a cDNA fragment (nucleotides 140 to 2306) encoding the full-length HEB protein into the cloning site of pBluescript. pE12R, containing a partial E12 cDNA, was kindly provided by C. Murre (36) . The ITF2 cDNA was a gift of T. Kadesch (22 cloning sites of pGEX-2T (Pharmacia, Piscataway, N.J.). Fusion protein was induced and purified with glutathione agarose beads (Sigma, St. Louis, Mo.) as described previously (30) . Antiserum against the fusion protein was produced by immunizing rabbits (CALTAG Laboratories, Healdsburg, Calif.). GST-HEB (amino acids 254 to 682 [23] ) was prepared by inserting the HEB cDNA (nucleotides 966 to 2306) at the EcoRI cloning site of pGEX-2T. Purified fusion protein was coupled with beaded agarose with the Reacti-Gel (6X) carbodiimidazole system (Pierce, Rockford, Ill.). GST-HEB beads (50 ,ll) were added into 100 ,ul of eightfold-diluted anti-E12 antiserum (kindly provided by C. Murre) at 4°C for 1 h to absorb antibodies against HEB. Absorption was repeated three times.
Site-directed mutagenesis. The minimal enhancer fragment was inserted into the polylinker site of pBluescript KS(+) vector, and single-strand DNA was prepared by infection of the bacteria with helper phage. Mutants were produced by using an oligonucleotide-mediated, gapped heteroduplex mutagenesis protocol according to the manual of the MutaGene in vitro mutagenesis kit (Bio-Rad). All mutants were confirmed by dideoxy-DNA sequence analysis with commercially available Sequenase reagents (United States Biochemical).
RESULTS
Three nuclear protein-DNA complexes are detected by EMSA with a CD4-3 oligonucleotide. The CD4-3 site, one of three nuclear protein binding sites in the minimal enhancer element, contains two adjacent E-box motifs (Fig. 1 ). To characterize proteins that bind to the CD4-3 site, a labeled synthetic oligonucleotide corresponding to the CD4-3 sequence was incubated with nuclear extract from the T-cell line SL3B and subjected to EMSA (Fig. 2B ). Using binding conditions with NaCl at 80 mM, we could detect a slowly migrating complex, CD4-3A, which was barely detectable in our previous analysis with NaCl at 200 mM (Fig. 2B , lane 1) (47) . The other complexes, CD4-3B and CD4-3C, have been detected with either condition (47) . All three complexes were specific, since they were inhibited by the wild-type CD4-3 oligonucleotide but not by a CD4-3 oligonucleotide mutated in both E-boxes or by control salmon sperm DNA (Fig. 2B, lanes 6 to 11) .
The CD4-1 binding site also contains an E-box motif and was hence tested for its ability to compete for protein binding to the CD4-3 site. The wild-type, but not the mutant, CD4-1 oligonucleotide competed for both CD4-3A and CD4-3C binding (Fig. 2B, lanes 2 to 5) , suggesting that both the CD4-3A and CD4-3C complexes contain factors which bind to the CD4-1 sequence. However, the CD4-1 oligonucleotide competed for CD4-3A binding less effectively than did the CD4-3 oligonucleotide, suggesting that CD4-3A nuclear protein interacts preferentially with the CD4-3 sequence (Fig. 2B, lanes 2 and 6) . No competition was observed between CD4-1 and the CD4-3B complex.
Mapping of the binding sites for the CD4-3 nuclear factors. A panel of CD4-3 double-stranded oligonucleotides with E-box mutations was synthesized and used in competition assays to localize sequences involved in the formation of the complexes. Ml has mutations in both E-boxes; M2, M4, and M6 have point mutations in the 5' E-box; and M3, M5, and M7 have point mutations in the 3' E-box ( Fig. 2A) . The 5' E-box mutants (M2, M4, and M6) competed efficiently for CD4-3C binding but not for CD4-3A binding (Fig. 2C) . In contrast, the 3' E-box mutants (M3, M5, and M7) competed efficiently for CD4-3A binding but not for CD4-3C binding. None of the mutant oligonucleotides competed efficiently for CD4-3B binding. Thus, single nucleotide substitutions in the upstream E-box, including a substitution inside the motif (M6), significantly reduced the level of CD4-3A binding, whereas those in the downstream E-box likewise affected CD4-3C binding. These results therefore indicate that the CD4-3A complex results from protein binding to the 5' E-box, whereas the CD4-3C complex involves binding to the 3' E-box.
Some cross-competition was observed in this assay when 50 ng of competing oligonucleotide was used. Therefore, nuclear proteins that bind strongly to one E-box motif appear to also bind weakly to the other E-box. The Ml oligonucleotide, which is mutated in both E-boxes, did not compete at all (Fig. 2C, lane 3) . Point mutations in either of the two E-boxes abolished competition for CD4-3B binding, suggesting that this complex involves protein interactions with sequences contained in both motifs.
In addition, oligonucleotides from both the CD4-1 site and the immunoglobulin enhancer cE2 site competed for CD4-3A binding, but only the CD4-1 oligonucleotide competed for CD4-3C binding (Fig. 2C, lanes 10 and 11) . Therefore, CD4-3A, but not CD4-3C, appears to contain KE2 binding factors, whereas both complexes appear to contain CD4-1 binding factors. The CD4-2 oligonucleotide containing the LEF binding site and control salmon sperm DNA did not compete for the formation of any of the complexes (Fig.  2C, lanes 12 and 13) .
Lymphoid specificity of the CD4-3A complex. We next examined the cell type specificity of the factors binding to the CD4-3 site. Nuclear extracts from various cell lines were incubated with the labeled CD4-3 oligonucleotide and subjected to EMSA (Fig. 3) . CD4-3B and CD4-3C were detectable in extracts from lymphoid and nonlymphoid cell lines, with the exception of the absence of CD4-3C from NIH 3T3 cells (Fig. 3) (47) . In contrast, the CD4-3A complex was detected, albeit at various levels, in extracts from all T-and B-cell lines, but not in extracts from the nonlymphoid cell lines P815, NIH 3T3, HeLa, K562, and U937 (Fig. 3) . Thus, CD4-3A is expressed in a lymphoid cell-specific manner, whereas CD4-3B and CD4-3C appear to be widely expressed.
The CD4-3A complex contains an oligomer of HEB and an E12-like protein. To determine whether any of the complexes contain E12-like proteins, the labeled CD4-3 oligonucleotide was incubated with nuclear extract from the T-cell line SL3B in the presence of antiserum against E12 and subjected to EMSA (Fig. 4) . The antiserum supershifted the CD4-3A MOL. CELL. BIOL. .
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.f. (Fig. 4 , lanes 5 to 7) but had no effect on the CD4-3B and CD4-3C complexes. Control preimmune serum had no effect on any of the complexes (Fig. 4, lanes 2 to 4) . Thus, the CD4-3A complex contains products of the E2A gene, such as E12 or E47, or related nuclear proteins.
Since CD4-3A was detected in a lymphoid cell-specific manner (Fig. 3) , we speculated that it may contain a lymphoid cell-specific partner pairing up with E12/E47 to form a heterodimer. We therefore screened a human thymus cDNA expression library with a labeled HLH motif of shPAN-2, a Syrian hamster homolog of E12 (18) . Several genes encoding HLH factors, including a gene identical to HEB (23) , were cloned by this approach. HEB, a protein closely related to E12/E47 and ITF2, was previously shown to bind in vitro to E-box motifs as a homooligomer or a heterooligomer with other bHLH factors, such as MyoD/myogenin and E12 (23) . Furthermore, mRNA of HEB was shown to be expressed predominantly in thymus and lymphoid cell lines (23, 39) , suggesting that HEB could be included in the CD4-3A complex.
To directly test whether HEB and E12 can bind to the CD4-3 site, in vitro-translated products were incubated with the labeled CD4-3 oligonucleotide and subjected to EMSA. Both HEB and E12R, a truncated form of E12 (36) , formed complexes with the CD4-3 probe as homodimers (Fig. SA,  lanes 2 and 4) with a mobility intermediate between those of the homodimer complexes (Fig. 5A, lane 3) . Additional bands migrating faster may represent products of alternative translation initiation codons, as previously suggested (23) . To localize the sequences interacting with these factors, CD4-3 oligonucleotides mutated in the E-boxes were used in competition assays (Fig. 5B) . The M4 oligonucleotide, which has a point mutation in the 5' E-box, competed poorly for binding of all factors. In contrast, the M5 oligonucleotide, which has a point mutation in the 3' E-box, competed as efficiently as the wild-type oligonucleotide. The ability of the in vitro-translated factors to directly bind to labeled mutant CD4-3 oligonucleotides was also tested (Fig. 5C ). Homodimers or heterodimers of HEB and E12R were clearly detected with the wild-type probe and the M5 probe but not with the M4 probe. These results indicate that HEB and E12, as homodimers or heterodimers, interact preferentially with the 5' E-box of the CD4-3 site, similar to the CD4-3A factor in nuclear extracts of lymphoid cell lines.
To determine whether HEB is present in the CD4-3A complex, a specific antiserum against HEB was raised by immunizing rabbits with a GST-HEB peptide-1 (amino acids 530 to 554) fusion protein. This peptide was selected from the HEB amino acid sequence by virtue of its relatively low homology with the closely related bHLH factors E12/E47 and ITF2. The antiserum against E12, which cross-reacts with in vitro-translated HEB (data not shown), was depleted of its cross-reactivity by preabsorption with a GST-HEB fusion protein coupled with agarose beads. The specificity of these antisera was tested on in vitro-translated proteins in EMSA with the CD4-3 oligonucleotide. The anti-HEB serum but not the preabsorbed anti-E12 serum supershifted in vitro-translated HEB, whereas the preabsorbed anti-E12 serum but not the anti-HEB serum recognized in vitrotranslated E12R (Fig. 6, lanes 1 to 6) . The specificity of the MOL. CELL. BIOL.
anti-HEB serum was further confirmed by its failure to react with a complex of in vitro-translated ITF2 and the CD4-3 oligonucleotide (data not shown). In contrast, the absorbed anti-E12 antiserum disrupted the ITF2-containing complex (data not shown).
The CD4-3A complex formed with nuclear extract of SL3B cells was recognized by both antisera (Fig. 6, lanes 7  to 9) , indicating that it contains a heterodimer or heterooligomer of HEB and E12 or an E12-related protein. A small amount of CD4-3A was not supershifted with anti-HEB, whereas all detectable CD4-3A was supershifted with anti-E12. This suggests that CD4-3A contains some homodimers of the E12-like factor or heterodimers of E12 with proteins other than HEB.
Effects of mutations in the CD4-3 site on CD4 enhancer activity. In a previous study, we showed that an intact CD4-3 site was required for T-cell-specific CD4 enhancer activity (47) . To further define the elements that are involved in enhancer function, we tested the activity of enhancers containing point mutations in the two E-box motifs of the CD4-3 site. The minimal enhancer fragments containing these mutations were subcloned upstream of the CD4 promoter-CAT plasmid (pCD4CAT). These plasmids were transfected into the T-cell line 1200M, and CAT activity was measured 2 days later. The point mutations in the 5' E-box abolished the enhancer activity completely (Fig. 7) . It is noteworthy that the substitution of a nucleotide inside the 5' E-box (CAGGIX to CAAG2i) also abolished enhancer activity (Fig. 7, M6 ). In the competition analysis, this same mutation disrupted CD4-3A binding (Fig. 2C, M6 ). In contrast, point mutations in the 3' E-box had only a slight effect on enhancer activity. Therefore, mutations that specifically disrupted the binding of CD4-3A nuclear factors, but not those that disrupted binding of CD4-3C factors, eliminated enhancer activity. Overexpression of Id protein inhibits CD4 enhancer function. To test the potential role of E12/E47 or related bHLH proteins in the function of the CD4 enhancer, a plasmid expressing Id-1, a negative regulator of E12/E47, was cotransfected with the CD4 enhancer-driven CAT plasmid into 1200M cells. Enhancer-dependent CAT activity was reduced by the cotransfection of a sense-oriented Id-1 expression plasmid in a dose-dependent manner. The expression of a control antisense-oriented Id-1 had only a minor effect on enhancer activity (Fig. 8) . Similar results were obtained with the human T-cell line Jurkat (data not shown). As Id-1 is known to form inactive heterodimers with bHLH proteins in general and with E2A gene products in particular, this result suggests that E12/E47-like proteins play a crucial role in CD4 enhancer activity in T cells.
DISCUSSION
In this study, we have identified a novel lymphoid cellspecific nuclear factor, CD4-3A, that contains the bHLH proteins HEB and E12/E47 or related proteins and that binds to a DNA sequence essential for the activity of the T-lymphocyte-specific CD4 enhancer. This factor binds preferentially to one of the two adjacent E-box motifs in the CD4-3 site of the enhancer; point mutations in this 5' E-box, but not in the 3' E-box, resulted in both the loss of formation of the CD4-3A complex on EMSA and the loss of CD4 enhancer activity in T cells. The CD4-3A complex was reactive with specific antibodies against HEB and E12/E47. Consistent with these results, in vitro-translated E12 and HEB, as either homodimers or heterodimers, bound specifically to the 5' E-box. In addition, expression of Id, which forms inactive dimers with E12/E47, inhibited enhancer function in transfected cells. Together, these results suggest that a heterodimer of HEB and an E12-like protein discriminates between the two adjacent E-box motifs and interacts functionally with the 5' E-box to mediate enhancer function in vivo. The CD4-3A complex was observed only with nuclear extracts from lymphoid cells, suggesting that either HEB or the E12-like factor is lymphoid cell specific. Tissue-specific bHLH heterodimers have previously been found in skeletal 1 2 3 4 5 6 7 8 9 10 (38) . Yet another possibility is that the HEB-E12 heterodimer may be modified in a tissue-specific patter or may associate with other lymphoid tissue-specific proteins to form the CD4-3A complex.
T`wo additional protein-DNA complexes, CD4-3B and a * . . . . CD4-3C, were detected with the CD4-3 probe in EMSA with both lymphoid and nonlymphoid cell nuclear extracts. Binding of the CD4-3C factor involves sequences in the 3', but not the 5', E-box, whereas formation of the CD4-3B complex requires sequences in both E-boxes. Neither of these complexes was reactive with antibodies against HEB or E12/ E47. Therefore, although CD4-3B interacts with sequences also recognized by CD4-3A, it is unlikely that the two factors have shared components. On the other hand, it is possible that CD4-3B contains CD4-3C in its complex. These findings are reminiscent of the observation that ubiquitous factors which do not contain MyoD, myogenin, or E12/E47-like proteins interact with the MEF1 site where the heterodimers of the myogenic bHLH proteins and E12/E47-like proteins bind (33) . Since point mutations in the 3' E-box, which abrogated formation of both CD4-3B and CD4-3C, had very little effect on enhancer activity, it is unlikely that these factors have a significant role in CD4 regulation. It is possible, however, that since the binding sites for CD4-3A and CD4-3B are overlapping, these factors compete with each other for binding to the 5' E-box. CD4-3B may thus regulate the accessibility of CD4-3A binding to the 5' E-box and may negatively regulate CD4 expression in development. Alternatively, these factors may interact with the same sequences simultaneously through contacts in the different grooves, as was observed with factors regulating the human beta interferon promoter (52 ization of CD4-3B and CD4-3C is necessary to understand the potential significance of these factors in CD4 gene regulation.
Although CD4-3A was detected in nuclear extracts from B-cell lines as well as in those from T-cell lines, the CD4 enhancer functioned predominantly in T cells in both transient transfection (47) and transgenic mouse systems (28) . In previous studies, we identified two additional nuclear factor binding sites within the CD4 enhancer, CD4-1 and CD4-2 ( Fig. 1) . Deletion of the region containing both CD4-1 and CD4-2 sites abolished enhancer activity, although mutations in these sites that eliminated formation of DNA-nuclear protein complexes had only a small detrimental effect on enhancer activity (47) . Taken together, these observations suggest that factors other than those observed in the CD4-3A complex are required for T-cell-specific activity. It is not yet clear whether these factors are those that form complexes with the CD4-1, CD4-2, and CD4-3 sites. The CD4-1 site, like CD4-3, contains an E-box motif (Fig. 1) (Fig. 2B, lanes 2 and 6) . Recently, the pre-B-and T-cell-specific high-mobility-group (HMG) family factor that binds to the CD4-2 site, LEF, was shown to have DNA bending activity (19) . It was proposed that, in the TCR-a enhancer, this factor facilitates the interaction of two flanking protein-DNA complexes. In the CD4 enhancer, the LEF binding site is similarly situated between two transcription factor binding sites (Fig. 1) . Binding of LEF to the CD4-2 site may thus bend the DNA to facilitate an interaction between the nuclear protein complexes binding to the CD4-1 and CD4-3 sites.
Expression of the CD4 gene is unusually regulated during T-cell development. It is positively regulated in the transition of immature CD4-CD8-to CD4+ CD8+ thymocytes and then apparently negatively regulated in a subset of double-positive cells that yield CD4-CD8+ cytotoxic T cells. Evidence of apparent transcriptional silencing of CD4 in the mature CD8+ cells comes from transgenic studies in which the CD4 enhancer, linked to the CD4 promoter, directed expression of a CD4 cDNA-genomic minigene in all T cells (12a). In contrast, a similar combination of the CD4 enhancer and promoter directed subset-specific expression of a CD4 genomic construct, suggesting that a transcriptional silencer, activated in CD8+ cells, acts on a discrete genomic sequence adjacent to the CD4 promoter (46a). During the transition from CD4-CD8-to CD4+ CD8+ cells, the CD4 enhancer appears to up-regulate CD4 gene transcription, most likely by interacting with multiple transcription factors including HEB, E12-like protein, and LEF. Further differentiation may involve activation of additional factors that modulate the interactions of the CD4 enhancer/promoter with its transcription factors, resulting in the down-regulation of CD4 gene expression in the CD4-CD8+ lineage. Regulation of the binding of bHLH factors to the CD4 enhancer may play a central role during this process of differentiation.
